Form 4: IRADIMED CFO Sells 10,651 Shares in Pre-Planned Trade

IRADIMED Corp's CFO, John Glenn, sold 10,651 shares of common stock for a weighted average price of $84.5143 in a pre-planned transaction.

Summary

• John Glenn, Chief Financial Officer of IRADIMED CORP (IRMD), disposed of 10,651 shares of common stock.
• The transaction occurred on November 10, 2025, and was executed under a Rule 10b5-1 pre-planned trading arrangement.
• The shares were sold at a weighted average price of $84.5143 per share, with individual trades ranging from $84.25 to $85.18.
• Following this transaction, John Glenn directly beneficially owns 2,500 shares of IRADIMED CORP common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a key executive selling a substantial number of shares, although the pre-planned nature (10b5-1) mitigates some of the immediate negative implications.

Positives

• The transaction was executed pursuant to a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new, non-public information.

Negatives

• A key executive, the Chief Financial Officer, reduced their direct beneficial ownership in the company by 10,651 shares.

Risks

• Reduced insider ownership by a key executive could be perceived by the market as a lack of confidence, potentially impacting investor sentiment.
• The sale of shares by a CFO, even if pre-planned, removes a portion of their direct financial alignment with shareholder interests.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report is specific to IRADIMED CORP and its Chief Financial Officer, John Glenn. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Stakeholder Impact

• Shareholders may perceive the reduction in direct insider ownership by the CFO as a negative signal, potentially impacting investor confidence.
• The pre-planned nature of the sale (10b5-1) offers transparency, which can be viewed positively by stakeholders concerned about fair trading practices.

Key Dates

Recommendation

While a CFO selling shares can be a negative signal, the transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new, non-public information. This mitigates the immediate negative impact, suggesting a 'hold' rather than an outright 'sell' unless other fundamental factors or news emerge. Investors should monitor future insider activity and company performance.

Keywords

IRADIMED, IRMD, Insider Sale, Form 4, John Glenn, CFO, Stock Transaction, 10b5-1 Plan